Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.79 SEK | -20.29% | -8.82% | -10.00% |
Feb. 28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
Feb. 21 | Enorama Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2021 | 12.8M 1.2M | Sales 2022 | 6.85M 642K | Capitalization | 28.05M 2.63M |
---|---|---|---|---|---|
Net income 2021 | -27M -2.53M | Net income 2022 | -42M -3.94M | EV / Sales 2021 | 12.7 x |
Net cash position 2021 | 8.41M 788K | Net cash position 2022 | 2.23M 209K | EV / Sales 2022 | 3.77 x |
P/E ratio 2021 |
-4.97
x | P/E ratio 2022 |
-0.68
x | Employees | 9 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 29.4% |
1 day | -20.29% | ||
1 week | -8.82% | ||
Current month | -0.36% | ||
1 month | -14.68% | ||
3 months | -65.98% | ||
6 months | -4.45% | ||
Current year | -10.00% |
Managers | Title | Age | Since |
---|---|---|---|
Annette Agerskov
CEO | Chief Executive Officer | 64 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 61 | 15-12-31 | |
- | - | ||
Daniel Schroeder
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 2.79 | -20.29% | 21 607 |
24-05-15 | 3.5 | +0.29% | 311 |
24-05-14 | 3.49 | +13.31% | 10,926 |
24-05-13 | 3.08 | +0.65% | 50,986 |
24-05-10 | 3.06 | +5.52% | 29,833 |
Delayed Quote Nasdaq Stockholm, May 16, 2024 at 03:08 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-10.00% | 13.41M | |
+21.00% | 43.92B | |
+24.56% | 23.09B | |
+19.66% | 15.35B | |
+13.11% | 13.61B | |
+46.00% | 12.02B | |
-10.14% | 7B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.07% | 5.6B |
- Stock Market
- Equities
- ERMA Stock